Ovid Therapeutics Announces Phase 1/1b Clinical Trial Submission for Oral KCC2 Activator OV4071

Reuters12-18 21:00

Ovid <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Announces Phase 1/1b Clinical Trial Submission for Oral KCC2 Activator OV4071

Ovid Therapeutics Inc. announced results from its Phase 1 study of OV350, the first KCC2 direct activator dosed in humans. The study met its primary objectives, demonstrating safety, tolerability, and pharmacokinetics of OV350. The results from this study will be submitted for presentation at a future congress. Ovid also reported that it will not advance OV350 IV further in the clinic, instead prioritizing the development of its oral KCC2 direct activator programs, including OV4071 and OV4041. The company plans to submit a regulatory application for a Phase 1/1b clinical trial of OV4071 in the first quarter of 2026, with initiation of clinical studies expected in the second quarter of 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ovid Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9604278-en) on December 18, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2592906847?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-18 21:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2592906847","market":"fut","top_or_hot":-1,"title":"Ovid Therapeutics Announces Phase 1/1b Clinical Trial Submission for Oral KCC2 Activator OV4071","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Ovid <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Announces Phase 1/1b Clinical Trial Submission for Oral KCC2 Activator OV4071\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/OVID\">Ovid Therapeutics Inc.</a> announced results from its Phase 1 study of OV350, the first KCC2 direct activator dosed in humans. The study met its primary objectives, demonstrating safety, tolerability, and pharmacokinetics of OV350. The results from this study will be submitted for presentation at a future congress. Ovid also reported that it will not advance OV350 IV further in the clinic, instead prioritizing the development of its oral KCC2 direct activator programs, including OV4071 and OV4041. The company plans to submit a regulatory application for a Phase 1/1b clinical trial of OV4071 in the first quarter of 2026, with initiation of clinical studies expected in the second quarter of 2026.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ovid Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9604278-en) on December 18, 2025, and is solely responsible for the information contained therein.</span></i>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ovid Therapeutics Announces Phase 1/1b Clinical Trial Submission for Oral KCC2 Activator OV4071</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOvid Therapeutics Announces Phase 1/1b Clinical Trial Submission for Oral KCC2 Activator OV4071\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-12-18 21:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Ovid <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Announces Phase 1/1b Clinical Trial Submission for Oral KCC2 Activator OV4071\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/OVID\">Ovid Therapeutics Inc.</a> announced results from its Phase 1 study of OV350, the first KCC2 direct activator dosed in humans. The study met its primary objectives, demonstrating safety, tolerability, and pharmacokinetics of OV350. The results from this study will be submitted for presentation at a future congress. Ovid also reported that it will not advance OV350 IV further in the clinic, instead prioritizing the development of its oral KCC2 direct activator programs, including OV4071 and OV4041. The company plans to submit a regulatory application for a Phase 1/1b clinical trial of OV4071 in the first quarter of 2026, with initiation of clinical studies expected in the second quarter of 2026.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ovid Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9604278-en) on December 18, 2025, and is solely responsible for the information contained therein.</span></i>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251218:nNDL75n40h:1","article_id":"2592906847","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2592906847","pubTimestamp":1766062830,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Ovid Therapeutics Inc. announced results from its Phase 1 study of OV350, the first KCC2 direct activator dosed in humans. The study met its primary objectives, demonstrating safety, tolerability, and pharmacokinetics of OV350. The results from this study will be submitted for presentation at a future congress. Ovid also reported that it will not advance OV350 IV further in the clinic, instead prioritizing the development of its oral KCC2 direct activator programs, including OV4071 and OV4041. The company plans to submit a regulatory application for a Phase 1/1b clinical trial of OV4071 in the first quarter of 2026, with initiation of clinical studies expected in the second quarter of 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","BK4585":"ETF&股票定投概念","SG9999014021.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) ACC","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","SG9999014005.SGD":"United Global Durable Equities Fund Acc SGD","NDAQ":"纳斯达克OMX交易所","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","SG9999014013.SGD":"United Global Durable Equities Fund Dis SGD","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","BK4588":"碎股","OVID":"Ovid Therapeutics Inc.","SG9999014039.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) INC","BK4112":"金融交易所和数据","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC"},"translate_title":"Ovid Therapeutics宣布提交口服KCC2激活剂OV4071的1/1b期临床试验","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"OVID":0.9,"NDAQ":0.9},"content_text":"Ovid Therapeutics Announces Phase 1/1b Clinical Trial Submission for Oral KCC2 Activator OV4071\n    \n\nOvid Therapeutics Inc. announced results from its Phase 1 study of OV350, the first KCC2 direct activator dosed in humans. The study met its primary objectives, demonstrating safety, tolerability, and pharmacokinetics of OV350. The results from this study will be submitted for presentation at a future congress. Ovid also reported that it will not advance OV350 IV further in the clinic, instead prioritizing the development of its oral KCC2 direct activator programs, including OV4071 and OV4041. The company plans to submit a regulatory application for a Phase 1/1b clinical trial of OV4071 in the first quarter of 2026, with initiation of clinical studies expected in the second quarter of 2026.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ovid Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9604278-en) on December 18, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2592906847","isCrawlerRequest":true}